MX2022015165A - Formas y composiciones de un agonista beta adrenégico. - Google Patents
Formas y composiciones de un agonista beta adrenégico.Info
- Publication number
- MX2022015165A MX2022015165A MX2022015165A MX2022015165A MX2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A MX 2022015165 A MX2022015165 A MX 2022015165A
- Authority
- MX
- Mexico
- Prior art keywords
- forms
- compositions
- beta adrenergic
- adrenergic agonist
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/90—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034900P | 2020-06-04 | 2020-06-04 | |
| PCT/US2021/035796 WO2021247934A1 (en) | 2020-06-04 | 2021-06-03 | Forms and compositions of a beta adrenergic agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015165A true MX2022015165A (es) | 2023-03-01 |
Family
ID=78829944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015165A MX2022015165A (es) | 2020-06-04 | 2021-06-03 | Formas y composiciones de un agonista beta adrenégico. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230219892A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161496A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734700B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230021075A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115989019B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021282582A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179993A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015165A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021247934A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11607395B2 (en) | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP2023541379A (ja) * | 2020-09-01 | 2023-10-02 | キュラセン セラピューティクス インコーポレイテッド | 神経系の疾患及び障害を改善するための組成物及び方法 |
| US12616667B2 (en) | 2021-11-15 | 2026-05-05 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| CN120583945A (zh) | 2023-01-20 | 2025-09-02 | 阿托基公司 | 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂 |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| WO2003072573A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| WO2011133226A2 (en) | 2010-04-22 | 2011-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| BR112013012994A2 (pt) * | 2010-11-24 | 2016-09-13 | Lithera Inc | formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno |
| US9320724B2 (en) | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| US9889087B2 (en) | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
| BR112018073227A2 (pt) * | 2016-05-13 | 2019-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | compostos moduladores do receptor adrenérgico e métodos de uso do mesmo |
| WO2018169742A1 (en) * | 2017-03-14 | 2018-09-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibtor |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| EP3806957A4 (en) * | 2018-06-14 | 2022-03-16 | Curasen Therapeutics, Inc. | METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| US10947196B2 (en) * | 2019-03-27 | 2021-03-16 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
-
2021
- 2021-06-03 JP JP2022574390A patent/JP7734700B2/ja active Active
- 2021-06-03 MX MX2022015165A patent/MX2022015165A/es unknown
- 2021-06-03 WO PCT/US2021/035796 patent/WO2021247934A1/en not_active Ceased
- 2021-06-03 AU AU2021282582A patent/AU2021282582A1/en active Pending
- 2021-06-03 EP EP21818923.1A patent/EP4161496A4/en active Pending
- 2021-06-03 US US18/007,726 patent/US20230219892A1/en active Pending
- 2021-06-03 CN CN202180048013.4A patent/CN115989019B/zh active Active
- 2021-06-03 KR KR1020237000115A patent/KR20230021075A/ko active Pending
- 2021-06-03 CA CA3179993A patent/CA3179993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115989019B (zh) | 2026-01-02 |
| EP4161496A1 (en) | 2023-04-12 |
| KR20230021075A (ko) | 2023-02-13 |
| CN115989019A (zh) | 2023-04-18 |
| JP7734700B2 (ja) | 2025-09-05 |
| EP4161496A4 (en) | 2024-08-21 |
| US20230219892A1 (en) | 2023-07-13 |
| CA3179993A1 (en) | 2021-12-09 |
| AU2021282582A1 (en) | 2023-02-02 |
| JP2023528450A (ja) | 2023-07-04 |
| WO2021247934A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY209784A (en) | Heterocyclic compound and use thereof | |
| ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
| MX2023013978A (es) | Composicion fungicida que contiene compuestos de oxadiazol. | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| PH12020551304A1 (en) | Novel crystalline forms | |
| UA96450C2 (ru) | Азолилметилоксираны, их применение для борьбы с фитопатогенными грибами, средство для защиты растений, способ борьбы с фитопатогенными грибами и посевной материал | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| TN2011000222A1 (en) | Melanocortin receptor agonists | |
| MX2020007562A (es) | Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion. | |
| PY2071938A (es) | Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas | |
| SG11201806682TA (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MX2025000174A (es) | Compuestos y metodos terapeuticos. | |
| DE602004024383D1 (de) | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists | |
| MX2020006370A (es) | Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas. | |
| MX2018001902A (es) | Aditivo para composiciones lubricantes que comprenden un compuesto de organomolibdeno que contiene azufre y sin azufre y un triazol. | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| NZ782087A (en) | Feed composition comprising hexahydro-β-acid component compounds and application thereof | |
| PH12022550859A1 (en) | 2-azaspiro[3.4]octane derivatives as m4 agonists | |
| PH12020551330A1 (en) | Insecticidal composition and use thereof | |
| CL2021000302A1 (es) | Proceso para la preparación de estimuladores de guanilato ciclasa soluble. (divisional de solicitud 202002283). | |
| MX2021004085A (es) | El uso de un agonista inverso de h3r para el tratamiento de la somnolencia diurna excesiva asociada con la enfermedad de parkinson (ep). | |
| TW200716607A (en) | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | |
| ZA202006181B (en) | Process for the preparation of iloprost | |
| WO2023278403A3 (en) | Crystalline hydrochloride salts of substituted tryptamines | |
| MX2023007382A (es) | Composiciones y métodos relacionados con compuestos que contienen biciclo [2.2.1] heptanamina di-sustituida. |